Amgen Inc. Interest Payable, Current
Amgen Inc. (AMGN) had Interest Payable, Current of $867.00 million as of 2024-12-31, per its 10-K filed 2025-02-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:InterestPayableCurrent · last filed 2025-02-14
- 2024-12-31: Interest Payable, Current $867.00M.
- 2023-12-31: Interest Payable, Current $936.00M.
- 2022-12-31: Interest Payable, Current $470.00M.
| Period end | Interest Payable, Current |
|---|---|
| 2024-12-31 | $867.00M 10-K · filed 2025-02-14 |
| 2023-12-31 | $936.00M 10-K · filed 2025-02-14 |
| 2022-12-31 | $470.00M 10-K · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |